TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

Stock Information for Eiger BioPharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Eiger BioPharmaceuticals Inc.

TCBP Announces Transition from Nasdaq to OTC Markets
TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
TCBP to Implement ADS Ratio Change
TCBP Announces H5N1 Proof of Concept Studies Intention

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.